Background:The European CE Mark approval study and the MOMENTUM 3 trial demonstrated safety and a reduction in hemocompatibility-related adverse events with the use of HeartMate 3 (HM3) device. This single-center study investigated the real-world experience in HM3 patients since FDA approval.Methods: This retrospective, observational study included patients implanted with the HM3 LVAD as a primary implant between October 2017 and March 2020. Patients were divided into trial group and postapproval group. The primary endpoint was survival at 6 months. Secondary endpoints were adverse events including pump thrombosis (requiring pump exchange), stroke, renal failure, acute limb ischemia, re-exploratory for bleeding, gastrointestinal bleeding, right ventricular failure, and driveline infection.Results: A total of 189 patients were implanted with HM3 device during the study period. 174 patients met the inclusion criteria: 82 patients in the trial group and 92 patients in the postapproval group. The postapproval group had younger patients, higher preoperative mean international normalized ratio, and greater numbers of patients with bridge to transplant (BTT) indications, IINTERMACS profile 1, and use of mechanical assist devices (other than IABP) than the trial group. Other characteristics between the two groups were comparable. Overall survival at 6 months in the postapproval group was 93.3% versus 93.8% (p = .88). The postapproval group demonstrated a statistically significant lower incidence of re-explorative surgery for bleeding (10.9% vs. 46.3, p = .01) than the trial group.
Conclusion:In this single-center study, the real-world 6-month survival in the postapproval group was comparable to the trial results. Further studies are needed to monitor long-term outcomes.
Background The European CE Mark approval study and the MOMENTUM 3 trial
demonstrated safety and a reduction in hemocompatibility-related adverse
events with use of HeartMate 3 (HM3) device. This single center study
investigated the real-world experience in HM3 patients since FDA
approval. Methods This retrospective, observational study included
patients implanted with the HM3 LVAD as a primary implant between
October 2017-March 2020. Patients were divided into trial group
and postapproval group. Primary endpoint was survival at 6 months.
Secondary endpoints were adverse events including pump thrombosis
(requiring pump exchange), stroke, renal failure, acute limb ischemia,
re-exploratory for bleeding, gastrointestinal bleeding, right
ventricular failure, and driveline infection. Results A total of 189
patients were implanted with HM3 device during the study period. 174
patients met the inclusion criteria: 82 patients in the trial group and
92 patients in the postapproval group. The postapproval group had
younger patients, higher pre-operative mean international normalized
ratio, and greater numbers of patients with bridge to transplant (BTT)
indications, IINTERMACS profile 1, and use of mechanical assist devices
(other than IABP) than the trial group. Other characteristics between
the two groups were comparable. Overall survival at 6 months in the
postapproval group was 93.3% vs. 93.8% ( p=0.88). The
postapproval group demonstrated a statistically significant lower
incidence of re-explorative surgery for bleeding (10.9% vs 46.3,
p=0.01) than the trial group. Conclusion In this single-center
study, the real-world 6-month survival in the postapproval group was
comparable to the trial results. Further studies are needed to monitor
long-term outcomes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.